OC
AKBA icon

Oppenheimer & Co’s Akebia Therapeutics AKBA Stock Holding History

Oppenheimer & Co’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-12,100
Closed -$59K – 1257
2019
Q2 		$59K Sell
12,100
-1,060
-8% -$6.03K ﹤0.01% 1277
2019
Q1 		$108K Buy
13,160
+935
+8% +$6.42K ﹤0.01% 1301
2018
Q4 		$68K Buy
+12,225
New +$95.7K ﹤0.01% 1200

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oppenheimer & Co's AKBA Position: Q3 2019 in Review

Oppenheimer & Co sold out of Akebia Therapeutics (AKBA) in Q3 2019, closing a stake of 12,100 shares — an estimated $59K sold.

Oppenheimer & Co first reported a position in AKBA in Q4 2018 and held it in 3 quarters. The position peaked at $108K in Q1 2019. 150 funds tracked by Wall St. Rank hold AKBA as of Q3 2019.

  • Oppenheimer & Co reported no remaining Akebia Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Oppenheimer & Co sold 12,100 Akebia Therapeutics shares in Q3 2019, an estimated $59K.
  • Oppenheimer & Co first reported a position in Akebia Therapeutics in Q4 2018 and held it in 3 quarters.
  • Oppenheimer & Co's Akebia Therapeutics position peaked at $108K in Q1 2019.
  • 150 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2019.

Based on Oppenheimer & Co's 13F filing for Q3 2019, filed 31 Oct 2019.